• University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
  • OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
  • FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
  • Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
  • Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
  • Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
  • Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
  • Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
  • FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
  • Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
  • Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
  • XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata